Proteonomix, Inc., a biotechnology company, is engaged in the development of therapeutics based upon the use of human cells and their derivatives, particularly in the areas of diabetes and cardiac diseases. The Proteonomix Family of companies includes Proteoderm, StromaCel, National Stem Cell, PRTMI and THOR Biopharma.
Proteoderm, Inc. is a wholly owned subsidiary that has developed an anti-aging line of skin care products. StromaCel, Inc. develops therapeutic modalities for the treatment of Cardiovascular Disease (CVD). National Stem Cell, Inc. is Proteonomix’s operating subsidiary. Proteonomix Regenerative Translational Medicine Institute, Inc. (“PRTMI”) intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine.
Proteonomix aims to achieve a leadership position in life enhancement regenerative stem cell therapies, services, and products through a combination of first to market technologies and innovative clinical trial strategies.
Let us hear your thoughts: Proteonomix, Inc. Message Board